The report provides a detailed analysis essential for establishing a Travoprost production plant. It encompasses all critical aspects necessary for Travoprost production, including the cost of Travoprost production, Travoprost plant cost, Travoprost production costs, and the overall Travoprost production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Travoprost production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Travoprost is an eye drop medication that is used to treat open-angle glaucoma and high eye pressure. It belongs to a class of drugs called prostaglandin analogues that work by copying natural eye chemicals to increase the drainage of fluid from the eye. It lowers intraocular pressure by 6.5 to 9 mmHg when used alone. In some cases, it is utilised in combination with other drops like timolol. It is suitable for adults as well as children from 2 months old up to 18 years old. It provides long-lasting pressure control for up to 84 hours after dosing, helping protect eyesight over time. Its common side effects are eye redness, eye discomfort, itching, pain, blurred or decreased vision, foreign body sensation, and dryness.
The market for Travoprost is influenced by rising glaucoma and ocular hypertension cases. The rise in the ageing population, increased eye health awareness, and healthcare expansion contribute to its market growth. Also, the technological advancements in ophthalmic delivery systems, once-daily dosing convenience, along with generic availability expands its applications.
The usage of combination therapies improves patient compliance, which further makes it a preferred option. The industrial Travoprost procurement is affected by the need for API suppliers with GMP certification, USDMF and CEP filings, and reliable supply chains. Other factors, like competitive pricing influenced by local production, regulatory approvals, and generic competition, further impact its sourcing strategies.
Raw Material for Travoprost Production
According to the Travoprost production plant project report, the key raw materials used in the production of Travoprost include 3-hydroxybenzotrifluoride, vinyl iodide precursor, and tricyclic ketone precursors.
Production Process of Travoprost
The extensive Travoprost production cost report consists of the following major industrial production process:
- From 3-hydroxybenzotrifluoride: The synthesis of Travoprost starts by using 3-hydroxybenzotrifluoride to build the high-purity tricyclic ketone intermediate. Along with this, parallel synthesis of enantiopure vinyl iodide intermediate, which couples via cuprate reaction to yield a single-isomer bicyclic ketone intermediate. The Baeyer-Villiger oxidation leads to the formation of a crystalline lactone intermediate, reduced by DIBAL-H to lactol. This is followed by Wittig olefination for the upper chain, esterification with isopropyl alcohol, and desilylation to get travoprost as the final product.
Travoprost appears as a clear, colourless to slightly yellow viscous oil with a molecular formula of C26H35F3O6 and molecular weight of 500.55-500.56 g/mol. It shows very high solubility in acetonitrile, methanol, octanol, and chloroform but remains practically insoluble in water. It has a LogP value of 3.84-4.6, making it strongly lipophilic. It has a boiling point of 584.8 degree Celsius with a density of 1.245 g/cm³. It requires storage at -20 degree Celsius under sealed, dry conditions protected from heat and light due to sensitivity. It undergoes hydrolysis by corneal esterases to its active free acid metabolite, selectively activating FP prostanoid receptors to enhance uveoscleral outflow. It has pKa values of 13.95 (acidic) and -2.9 (basic), a polar surface area of 96.22 Ų, and 14 rotatable bonds that support its pharmacological penetration.